Radiopharm is preparing a pivotal Phase 3 study of RAD101, reported positive RAD301 imaging data, and reached the fourth HEAT dosing group. A manufacturing and distribution partnership and A$5.9 million tax refund support the update, but no quarterly financial figures are given.
The FDA meeting gives Radiopharm a path toward a larger test of RAD101. Positive RAD301 imaging results and a production and distribution partner add support. The story gives no quarterly figures, so it does not show the company's cash use or costs.
Follow Radiopharm Theranostics (RADX) free. When we publish a story about it, you get the plain-English explanation as an alert.
Get alerts for RADX